Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Astellas Provides Update on Fezolinetant New Drug Application in U.S.
Astellas Pharma has announced the US Food and Drug Administration (FDA) notified the company that […]
Trodelvy Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
Gilead Sciences has announced new and updated positive results from three cohorts of the Phase 2 […]
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
Actinium Pharmaceuticals, a leader in the development of targeted radiotherapies, today announced positive results for […]
Government Plans to Bolster Patient Safety and Boost Support for Frontline Staff by Streamlining the System for Healthcare Regulators
The government has reaffirmed its commitment to streamline the system, improve patient safety and expand […]
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Takeda has announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 […]
Patrick Jeukenne, Aptar Pharma, On Drug Delivery Devices
In the video, Patrick Jeukenne, VP of Strategy Business Development & Marketing at Aptar Pharma, […]
Abivax appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer
Abivax SA, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the […]
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced that the […]
Maze Therapeutics to Present Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
Maze Therapeutics, a company translating genetic insights into new precision medicines, has announced that the […]
Charter Healthcare Names New CEO and COO
Charter Healthcare, the post-acute provider platform of Pharos Capital Group, LLC, announced today that it […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more